Ames, F. R. and Cridland, S. Anticonvulsant impact of cannabidiol. S.Afr.Med.J. 1-4-1986;69(1):14. View summary.
Barnes, M. P. Sativex: scientific efficacy and tolerability within the therapy of signs of a number of sclerosis and neuropathic ache. Knowledgeable.Opin.Pharmacother. 2006;7(5):607-615. View summary.
Carlini, E. A. and Cunha, J. M. Hypnotic and antiepileptic results of cannabidiol. J Clin Pharmacol 1981;21(8-9 Suppl):417S-427S. View summary.
Collin, C., Davies, P., Mutiboko, I. Ok., and Ratcliffe, S. Randomized managed trial of cannabis-based drugs in spasticity brought on by a number of sclerosis. Eur.J.Neurol. 2007;14(3):290-296. View summary.
Collin, C., Ehler, E., Waberzinek, G., Alsindi, Z., Davies, P., Powell, Ok., Notcutt, W., O’Leary, C., Ratcliffe, S., Novakova, I., Zapletalova, O., Pikova, J., and Ambler, Z. A double-blind, randomized, placebo-controlled, parallel-group research of Sativex, in topics with signs of spasticity as a result of a number of sclerosis. Neurol.Res. 2010;32(5):451-459. View summary.
Consroe, P., Kennedy, Ok., and Schram, Ok. Assay of plasma cannabidiol by capillary gasoline chromatography/ion lure mass spectroscopy following high-dose repeated every day oral administration in people. Pharmacol Biochem.Behav. 1991;40(3):517-522. View summary.
Consroe, P., Laguna, J., Allender, J., Snider, S., Stern, L., Sandyk, R., Kennedy, Ok., and Schram, Ok. Managed scientific trial of cannabidiol in Huntington’s illness. Pharmacol Biochem.Behav. 1991;40(3):701-708. View summary.
Cunha, J. M., Carlini, E. A., Pereira, A. E., Ramos, O. L., Pimentel, C., Gagliardi, R., Sanvito, W. L., Lander, N., and Mechoulam, R. Persistent administration of cannabidiol to wholesome volunteers and epileptic sufferers. Pharmacology 1980;21(3):175-185. View summary.
Harvey, D. J., Samara, E., and Mechoulam, R. Comparative metabolism of cannabidiol in canine, rat and man. Pharmacol Biochem.Behav. 1991;40(3):523-532. View summary.
Iuvone, T., Esposito, G., Esposito, R., Santamaria, R., Di Rosa, M., and Izzo, A. A. Neuroprotective impact of cannabidiol, a non-psychoactive part from Hashish sativa, on beta-amyloid-induced toxicity in PC12 cells. J Neurochem. 2004;89(1):134-141. View summary.
Ohlsson, A., Lindgren, J. E., Andersson, S., Agurell, S., Gillespie, H., and Hollister, L. E. Single-dose kinetics of deuterium-labelled cannabidiol in man after smoking and intravenous administration. Biomed.Environ Mass Spectrom. 1986;13(2):77-83. View summary.
Srivastava, M. D., Srivastava, B. I., and Brouhard, B. Delta9 tetrahydrocannabinol and cannabidiol alter cytokine manufacturing by human immune cells. Immunopharmacology 1998;40(3):179-185. View summary.
Trembly B, Sherman M. Double-blind scientific research of cannabidiol as a secondary anticonvulsant. Marijuana ’90 Worldwide Convention on Hashish and Cannabinoids 1990;2:5.
Wade, D. T., Collin, C., Stott, C., and Duncombe, P. Meta-analysis of the efficacy and security of Sativex (nabiximols), on spasticity in folks with a number of sclerosis. Mult.Scler. 2010;16(6):707-714. View summary.
Wade, D. T., Makela, P., Robson, P., Home, H., and Bateman, C. Do cannabis-based medicinal extracts have basic or particular results on signs in a number of sclerosis? A double-blind, randomized, placebo-controlled research on 160 sufferers. Mult.Scler. 2004;10(4):434-441. View summary.
Wade, D. T., Robson, P., Home, H., Makela, P., and Aram, J. A preliminary managed research to find out whether or not whole-plant hashish extracts can enhance intractable neurogenic signs. Clin.Rehabil. 2003;17(1):21-29. View summary.
Watzl, B., Scuderi, P., and Watson, R. R. Marijuana parts stimulate human peripheral blood mononuclear cell secretion of interferon-gamma and suppress interleukin-1 alpha in vitro. Int J Immunopharmacol. 1991;13(8):1091-1097. View summary.
Aviello G, Romano B, Borrelli F, et al. Chemopreventive impact of the non-psychotropic phytocannabinoid cannabidiol on experimental colon most cancers. J Mol Med (Berl) 2012;90(8):925-34. View summary.
Bergamaschi MM, Queiroz RH, Chagas MH, et al. Cannabidiol reduces the nervousness induced by simulated public talking in treatment-naïve social phobia sufferers. Neuropsychopharmacology 2011;36(6):1219-26. View summary.
Bisogno T, Di Marzo Y. The position of the endocannabinoid system in Alzheimer’s illness: info and hypotheses. Curr Pharm Des 2008;14(23):2299-3305. View summary.
Booz GW. Cannabidiol as an emergent therapeutic technique for lessening the impression of irritation on oxidative stress. Free Radic Biol Med 2011;51(5):1054-61. View summary.
Bornheim LM, Everhart ET, Li J, Correia MA. Characterization of cannabidiol-mediated cytochrome P450 inactivation. Biochem Pharmacol 1993;45(6):1323-31. View summary.
Brady CM, DasGupta R, Dalton C, et al. An open-label research of cannabis-based extracts for bladder dysfuntion in superior a number of sclerosis. Mult Scler 2004;10(4):425-33. View summary.
Campos AC, Moreira FA, Gomes FV, et al. A number of mechanisms concerned within the large-spectrum therapeutic potential of cannabidiol in psychiatric issues. Philos Trans R Soc Lond B Biol Sci 2012;367(1607):3364-78. View summary.
Cannabidiol Now Exhibiting Up In Dietary Dietary supplements. Pure Medicines Web page. Obtainable at: Accessed: Could 31, 2015.
Carroll CB, Bain PG, Teare L, et al. Hashish for dyskinesia in Parkinson illness: a randomized double-blind crossover research. Neurology 2004;63(7):1245-50. View summary.
Consroe P, Sandyk R, Snider SR. Open label analysis of cannabidiol in dystonic motion issues. Int J Neurosci 1986;30(4):277-82. View summary.
Crippa JA, Derenusson GN, Ferrari TB, et al. Neural foundation of anxiolytic results of cannabidiol (CBD) in generalized social nervousness dysfunction: a preliminary report. J Psychopharmacol 2011;25(1):121-30. View summary.
Dalterio S, Steger R, Mayfield D, Bartke A. Early cannabinoid publicity influences neuroendocrine and reproductive features in mice: II. Postnatal results. Pharmacol Biochem Behav 1984;20(1):115-23. View summary.
Devinsky O, Cilio MR, Cross H, et al. Cannabidiol: pharmacology and potential therapeutic position in epilepsy and different neuropsychiatric issues. Epilepsia 2014;55(6):791-802. View summary.
Englund A, Morrison PD, Nottage J, et al. Cannabidiol inhibits THC-elicited paranoid signs and hippocampal-dependent reminiscence impairment. J Psychopharmacol 2013;27(1):19-27. View summary.
Esposito G, De Filippis D, Maiuri MC, et al. Cannabidiol inhibits inducible nitric oxide synthase protein expression and nitric oxide manufacturing in beta-amyloid stimulated PC12 neurons by means of p38 MAP kinase and NF-kappaB involvement. Neurosci Lett 2006;399(1-2):91-5. View summary.
Esposito G, Scuderi C, Savani C, et al. Cannabidiol in vivo blunts beta-amyloid induced neuroinflammation by suppressing IL-1beta and iNOS expression. Br J Pharmacol 2007;151(8):1272-9. View summary.
FDA and Marijuana: Questions and Solutions. U.S. Meals and Drug Administration Web page. Obtainable at: Accessed: Could 31, 2015.
Formukong EA, Evans AT, Evans FJ. Analgesic and anti inflammatory exercise of constituents of Hashish sativa L. Irritation 1988;12(4):361-71. View summary.
Guimaraes FS, Chairetti TM, Graeff FG, Zuardi AW. Antianxiety impact of cannabidiol within the elevated plus-maze. Psychopharmacology (Berl) 1990;100(4):558-9. View summary.
Guimaraes VM, Zuardi AW, Del Bel EA, Guimaraes FS. Cannabidiol will increase Fos expression within the nucleus accumbens however not within the dorsal striatum. Life Sci 2004;75(5):633-8. View summary.
Harvey DJ. Absorption, distribution, and biotransformation of the cannabinoids. Marijuana and Drugs. 1999;91-103.
Historical past. GW Prescribed drugs Web page. Obtainable at: Accessed: Could 27, 2015.
Iuvone T, Esposito G, De Filippis D, et al. Cannabidiol: a promising new drug for neurodegenerative issues? CNS Neurosci Ther 2009;15(1):65-75. View summary.
Izzo AA, Borelli F, Capasso R, et al. Non-psychotropic plant cannabinoids: new therapeutic alternatives from an historical herb. Traits Pharmacol Sci 2009;30(10):515-27. View summary.
Kavia RB, De Ridder D, Constantinescu CS, et al. Randomized managed trial of Sativex to deal with detrusor overactivity in a number of sclerosis. Mult Scler 2010;16(11):1349-59. View summary.
Lee CY, Wey SP, Liao MH, et al. A comparative research on cannabidiol-induced apoptosis in murine thymocytes and EL-4 thymoma cells. Int Immunopharmacol 2008;8(5):732-40. View summary.
Leighty EG, Fentiman AF Jr, Foltz RL. Lengthy-retained metabolites of delta9- and delta8-tetrahydrocannabinols recognized as novel fatty acid conjugates. Res Commun Chem Pathol Pharmacol 1976;14(1):13-28. View summary.
Leweke FM, Kranaster L, Pahlisch F, et al. The efficacy of cannabidiol within the therapy of schizophrenia – a translational strategy. Schizophr Bull 2011;37(Suppl 1):313.
Leweke FM, Piomelli D, Pahlisch F, et al. Cannabidiol enhances anandamide signaling and alleviates psychotic signs of schizophrenia. Transl Psychiatry 2012;2:e94. View summary.
Lengthy LE, Chesworth R, Huang XF, et al. A behavioral comparability of acute and persistent Delta9-tetrahydrocannabinol and cannabidiol in C57BL/6JArc mice. Int J Neuropsychopharmacol 2010;13(7):861-76. View summary.
Magen I, Avraham Y, Ackerman Z, et al. Cannabidiol ameliorates cognitive and motor impairments in mice with bile duct ligation. J Hepatol 2009;51(3):528-34. View summary.
Malfait AM, Gallily R, Sumariwalla PF, et al. The non-psychoactive cannabis-constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc Natl Acad Sci USA 2000;97:9561-6. View summary.
Massi P, Solinas M, Cinquina V, Parolaro D. Cannabidiol as a possible anticancer drug. Br J Clin Pharmacol 2013;75(2):303-12. View summary.
Matsuyama SS, Fu TK. In vivo cytogenetic results of cannabinoids. J Clin Psychopharmacol 1981;1(3):135-40. View summary.
Mechoulam R, Parker LA, Gallily R. Cannabidiol: an summary of some pharmacological facets. J Clin Pharmacol 2002;42(11 Suppl):11S-19S. View summary.
Monti JM. Hypnoticlike results of cannabidiol within the rat. Psychopharmacology (Berl) 1977;55(3):263-5. View summary.
Moreira FA, Guimaraes FS. Cannabidiol inhibits the hyperlocomotion induced by psychomimetic medication in mice. Eur J Pharmacol 2005;512(2-3):199-205. View summary.
Morgan CJ, Das RK, Joye A, et al. Cannabidiol reduces cigarette consumption in tobacco people who smoke: preliminary findings. Addict Behav 2013;38(9):2433-6. View summary.
Murillo-Rodriguez E, Millan-Aldaco D, Palomero-Rivero M, et al. Cannabidiol, a constituent of Hashish sativa, modulates sleep in rats. FEBS Lett 2006;580(18):4337-45. View summary.
Notcutt W, Langford R, Davies P, et al. A placebo-controlled, parallel group, randomized withdrawal research of topics with signs of spasticity as a result of a number of sclerosis who’re receiving long-term Sativex (nabiximols). Mult Scler 2012;18(2):219-28. View summary.
Novotna A, Mares J, Ratcliffe S, et al. A randomized, double-blind, placebo-controlled, parallel-group, enriched-design research of nabiximols* (Sativex), as add-on remedy, in topics with refractory spasticity trigger by a number of sclerosis. Eur J Neurol 2011;18(9):1122-31. View summary.
Overview. GW Prescribed drugs Web page. Obtainable at: Accessed: Could 31, 2015.
Pertwee RG. The varied CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delat9-tetrahydrocannabivarin. Br J Pharmacol 2008;153:199-215. View summary.
Pickens JT. Sedative exercise of hashish in relation to its delta’-trans-tetrahydrocannabinol and cannabidiol content material. Br J Pharmacol 1981;72(4):649-56. View summary.
Rosenkrantz H, Fleischman RW, Grant RJ. Toxicity of short-term administration of cannabinoids to rhesus monkeys. Toxicol Appl Pharmacol 1981;58(1):118-31. View summary.
Samara E, Bialer M, Mechoulam R. Pharmacokinetics of cannabidiol in canines. Drug Metab Dispos 1988;16(3):469-72. View summary.
Sativex oromucosal spray. Abstract of product traits. GW Pharma, Ltd. Obtainable at: Up to date: Could 2015. Accessed: Could 31, 2015.
Schubart CD, Sommer IE, Fusar-Poli P, et al. Cannabidiol as a possible therapy for psychosis. Eur Neuropsychopharmacol 2014;24(1):51-64. View summary.
Schubart CD, Sommer IE, van Gastel WA, et al. Hashish with excessive cannabidiol content material is related to fewer psychotic experiences. Schizophr Res 2011;130(1-3):216-21. View summary.
Serpell MG, Notcutt W, Collin C. Sativex long-term use: an open-label trial in sufferers with spasticity as a result of a number of sclerosis. J Neurol 2013;260(1):285-95. View summary.
Shrivastava A, Kuzontkoski PM, Groopman JE, Prasad A. Cannabidiol induces programmed cell dying in breast most cancers cells by coordinating the cross-talk between apoptosis and autophagy. Mol Most cancers Ther 2011;10(7):1161-72. View summary.
Toth CC, Jedrzejewski NM, Ellis CL, Frey WH. Cannabinoid-mediated modulation of neuropathic ache and microglial accumulation in a mannequin of murine sort 1 diabetic peripheral neuropathic ache. Mol Ache 2010;6:16. View summary.
Valvassori SS, Elias G, de Souza B, et al. Results of cannabidiol on amphetamine-induced oxidative stress era in an animal mannequin of mania. J Psychopharmacol 2011;25(2):274-80. View summary.
Wade DT, Makela PM, Home H, et al. Lengthy-term use of a cannabis-based therapy in spasticity and different signs in a number of sclerosis. Mult Scler 2006;12(5):639-45. View summary.
Yadav V, Bever C Jr, Bowen J, et al. Abstract of evidence-based guideline: complementary and various drugs in a number of sclerosis: report of the rule of thumb growth subcommittee of the American Academy of Neurology. Neurology. 2014;82(12):1083-92. View summary.
Yamaori S, Ebisawa J, Okushima Y, et al. Potent inhibition of human cytochrome P450 3A isoforms by cannabidiol: position of phenolic hydroxyl teams within the resorcinol moiety. Life Sci 2011;88(15-16):730-6. View summary.
Yamaori S, Kushihara M, Yamamoto I, Watanabe Ok. Characterization of main phytocannabinoids, cannabidiol and cannabinol, as isoform-selective potent inhibitors of human CYP1 enzymes. Biochem Pharmacol 2010;79(11):1691-8. View summary.
Yamaori S, Maeda C, Yamamoto I, Watanabe Ok. Differential inhibition of human cytochrome P450 2A6 and 2B6 by main phytocannabinoids. Forensic Toxicol 2011;29:117-24.
Yamaori S, Okamoto Y, Yamamoto I, Watanabe Ok. Cannabidiol, a significant phytocannabinoid, as a potent atypical inhibitor for CYP2D6. Drug Metab Dispos 2011;39(11):2049-56. View summary.
Zuardi A, Crippa J, Dursun S, et al. Cannabidiol was ineffective for manic episode of bipolar affective dysfunction. J Psychopharmacol 2010;24(1):135-7. View summary.
Zuardi AW, Cosme RA, Graeff FG, Guimaraes FS. Results of ipsapirone and cannabidiol on human experimental nervousness. J Psychopharmacol 1993;7(1 Suppl):82-8. View summary.
Zuardi AW, Crippa JA, Hallak JE, et al. Cannabidiol for the therapy of psychosis in Parkinson’s illness. J Psychopharmacol 2009;23(8):979-83. View summary.
Zuardi AW, Crippa JA, Hallak JE, et al. Cannabidiol, a Hashish sativa constituent, as an antipsychotic drug. Braz J Med Biol Res 2006;39(4):421-9. View summary.
Zuardi AW, Morais SL, Guimaraes FS, Mechoulam R. Antipsychotic impact of cannabidiol. J Clin Psychiatry 1995;56(10):485-6. View summary.
Zuardi AW. Cannabidiol: from an inactive cannabinoid to a drug with broad spectrum of motion. Rev Bras Psiquiatr 2008;30(3):271-80. View summary.
Ames, F. R. and Cridland, S. Anticonvulsant impact of cannabidiol. S.Afr.Med.J. 1-4-1986;69(1):14. View summary.
Barnes, M. P. Sativex: scientific efficacy and tolerability within the therapy of signs of a number of sclerosis and neuropathic ache. Knowledgeable.Opin.Pharmacother. 2006;7(5):607-615. View summary.
Collin, C., Davies, P., Mutiboko, I. Ok., and Ratcliffe, S. Randomized managed trial of cannabis-based drugs in spasticity brought on by a number of sclerosis. Eur.J.Neurol. 2007;14(3):290-296. View summary.
Collin, C., Ehler, E., Waberzinek, G., Alsindi, Z., Davies, P., Powell, Ok., Notcutt, W., O’Leary, C., Ratcliffe, S., Novakova, I., Zapletalova, O., Pikova, J., and Ambler, Z. A double-blind, randomized, placebo-controlled, parallel-group research of Sativex, in topics with signs of spasticity as a result of a number of sclerosis. Neurol.Res. 2010;32(5):451-459. View summary.
Consroe, P., Kennedy, Ok., and Schram, Ok. Assay of plasma cannabidiol by capillary gasoline chromatography/ion lure mass spectroscopy following high-dose repeated every day oral administration in people. Pharmacol Biochem.Behav. 1991;40(3):517-522. View summary.
Consroe, P., Laguna, J., Allender, J., Snider, S., Stern, L., Sandyk, R., Kennedy, Ok., and Schram, Ok. Managed scientific trial of cannabidiol in Huntington’s illness. Pharmacol Biochem.Behav. 1991;40(3):701-708. View summary.
Crippa, J. A., Zuardi, A. W., Garrido, G. E., Wichert-Ana, L., Guarnieri, R., Ferrari, L., Azevedo-Marques, P. M., Hallak, J. E., McGuire, P. Ok., and Filho, Busatto G. Results of cannabidiol (CBD) on regional cerebral blood stream. Neuropsychopharmacology 2004;29(2):417-426. View summary.
Crippa, J. A., Zuardi, A. W., Martin-Santos, R., Bhattacharyya, S., Atakan, Z., McGuire, P., and Fusar-Poli, P. Hashish and nervousness: a crucial assessment of the proof. Hum.Psychopharmacol. 2009;24(7):515-523. View summary.
Cunha, J. M., Carlini, E. A., Pereira, A. E., Ramos, O. L., Pimentel, C., Gagliardi, R., Sanvito, W. L., Lander, N., and Mechoulam, R. Persistent administration of cannabidiol to wholesome volunteers and epileptic sufferers. Pharmacology 1980;21(3):175-185. View summary.
Harvey, D. J., Samara, E., and Mechoulam, R. Comparative metabolism of cannabidiol in canine, rat and man. Pharmacol Biochem.Behav. 1991;40(3):523-532. View summary.
Iuvone, T., Esposito, G., Esposito, R., Santamaria, R., Di Rosa, M., and Izzo, A. A. Neuroprotective impact of cannabidiol, a non-psychoactive part from Hashish sativa, on beta-amyloid-induced toxicity in PC12 cells. J Neurochem. 2004;89(1):134-141. View summary.
Massi, P., Vaccani, A., Bianchessi, S., Costa, B., Macchi, P., and Parolaro, D. The non-psychoactive cannabidiol triggers caspase activation and oxidative stress in human glioma cells. Cell Mol.Life Sci. 2006;63(17):2057-2066. View summary.
Massi, P., Vaccani, A., Ceruti, S., Colombo, A., Abbracchio, M. P., and Parolaro, D. Antitumor results of cannabidiol, a nonpsychoactive cannabinoid, on human glioma cell strains. J Pharmacol Exp.Ther. 2004;308(3):838-845. View summary.
Ohlsson, A., Lindgren, J. E., Andersson, S., Agurell, S., Gillespie, H., and Hollister, L. E. Single-dose kinetics of deuterium-labelled cannabidiol in man after smoking and intravenous administration. Biomed.Environ Mass Spectrom. 1986;13(2):77-83. View summary.
Srivastava, M. D., Srivastava, B. I., and Brouhard, B. Delta9 tetrahydrocannabinol and cannabidiol alter cytokine manufacturing by human immune cells. Immunopharmacology 1998;40(3):179-185. View summary.
Trembly B, Sherman M. Double-blind scientific research of cannabidiol as a secondary anticonvulsant. Marijuana ’90 Worldwide Convention on Hashish and Cannabinoids 1990;2:5.
Wade, D. T., Collin, C., Stott, C., and Duncombe, P. Meta-analysis of the efficacy and security of Sativex (nabiximols), on spasticity in folks with a number of sclerosis. Mult.Scler. 2010;16(6):707-714. View summary.
Wade, D. T., Makela, P., Robson, P., Home, H., and Bateman, C. Do cannabis-based medicinal extracts have basic or particular results on signs in a number of sclerosis? A double-blind, randomized, placebo-controlled research on 160 sufferers. Mult.Scler. 2004;10(4):434-441. View summary.
Wade, D. T., Robson, P., Home, H., Makela, P., and Aram, J. A preliminary managed research to find out whether or not whole-plant hashish extracts can enhance intractable neurogenic signs. Clin.Rehabil. 2003;17(1):21-29. View summary.
Watzl, B., Scuderi, P., and Watson, R. R. Marijuana parts stimulate human peripheral blood mononuclear cell secretion of interferon-gamma and suppress interleukin-1 alpha in vitro. Int J Immunopharmacol. 1991;13(8):1091-1097. View summary.
Weiss, L., Zeira, M., Reich, S., Har-Noy, M., Mechoulam, R., Slavin, S., and Gallily, R. Cannabidiol lowers incidence of diabetes in non-obese diabetic mice. Autoimmunity 2006;39(2):143-151. View summary.
Zuardi, A. W., Shirakawa, I., Finkelfarb, E., and Karniol, I. G. Motion of cannabidiol on the nervousness and different results produced by delta 9-THC in regular topics. Psychopharmacology (Berl) 1982;76(3):245-250. View summary.
“GW Prescribed drugs plc and Its U.S. Subsidiary Greenwich Biosciences, Inc. Announce That
EPIDIOLEX® (cannabidiol) Oral Answer Has Been Descheduled And Is No Longer A Managed
Substance.” GW Prescribed drugs, 6 April 2020. Press launch.
97021 Jadoon KA, Ratcliffe SH, Barrett DA, et al. Efficacy and security of cannabidiol and tetrahydrocannabivarin on glycemic and lipid parameters in sufferers with sort 2 diabetes: a randomized, double-blind, placebo-controlled, parallel group pilot research. Diabetes Care. 2016 Oct;39(10):1777-86. View summary.
Agriculture Enchancment Act, S. 10113, one hundred and fifteenth Cong. (2018) or S. 12619, one hundred and fifteenth Cong. (2018).
Anderson LL, Absalom NL, Abelev SV, et al. Coadministered cannabidiol and clobazam: Preclinical proof for each pharmacodynamic and pharmacokinetic interactions. Epilepsia. 2019. View summary.
Anderson LL, Doohan PT, Oldfield L, et al. Citalopram and Cannabidiol: In Vitro and In Vivo Proof of Pharmacokinetic Interactions Related to the Remedy of Nervousness Problems in Younger Folks. J Clin Psychopharmacol. 2021. View summary.
Appiah-Kusi E, Petros N, Wilson R, et al. Results of short-term cannabidiol therapy on response to social stress in topics at scientific excessive danger of creating psychosis.
Psychopharmacology (Berl). 2020 Jan 8.
View summary.
Arkell TR, Lintzeris N, Kevin RC, et al. Cannabidiol (CBD) content material in vaporized hashish doesn’t stop tetrahydrocannabinol (THC)-induced impairment of driving and cognition. Psychopharmacology (Berl). 2019;236(9):2713-2724. View summary.
Arkell TR, Vinckenbosch F, Kevin RC, Theunissen EL, McGregor IS, Ramaekers JG. Impact of Cannabidiol and ?9-Tetrahydrocannabinol on Driving Efficiency: A Randomized Scientific Trial. JAMA. 2020;324(21):2177-2186. View summary.
Arout CA, Haney M, Herrmann ES, Bedi G, Cooper ZD. The dose-dependent analgesic results, abuse legal responsibility, security and tolerability of oral cannabidiol in wholesome people. Br J Clin Pharmacol. 2021. View summary.
Aviello G, Romano B, Borrelli F, et al. Chemopreventive impact of the non-psychotropic phytocannabinoid cannabidiol on experimental colon most cancers. J Mol Med (Berl) 2012;90(8):925-34. View summary.
Baranowska-Kuczko M, Kozlowska H, Kloza M, et al. Vasoprotective Endothelial Results of Persistent Cannabidiol Remedy and Its Affect on the Endocannabinoid System in Rats with Main and Secondary Hypertension. Prescribed drugs (Basel) 2021;14(11):1120. View summary.
Bass J, Linz DR. A Case of Toxicity from Cannabidiol Gummy Ingestion. Cureus. 2020;12(4):e7688. View summary.
Bebee B, Taylor DM, Bourke E, et al. The CANBACK trial: a randomised, managed scientific trial of oral cannabidiol for folks presenting to the emergency division with acute low again ache. Med J Aust. 2021;214(8):370-375. View summary.
Ben-Menachem E, Gunning B, Arenas Cabrera CM, et al. A Part II Randomized Trial to Discover the Potential for Pharmacokinetic Drug-Drug Interactions with Stiripentol or Valproate when Mixed with Cannabidiol in Sufferers with Epilepsy. CNS Medicine. 2020;34(6):661-672. View summary.
Bergamaschi MM, Queiroz RH, Chagas MH, et al. Cannabidiol reduces the nervousness induced by simulated public talking in treatment-naïve social phobia sufferers. Neuropsychopharmacology 2011;36(6):1219-26. View summary.
Berger BA, Stolz U, Colvin J, Otten EJ. Epidemiology of cannabidiol associated instances reported within the Nationwide Poison Knowledge System – 2019-2020. Am J Emerg Med. 2021;48:218-223. View summary.
Bergeria CL, Spindle TR, Cone EJ, et al. Pharmacokinetic Profile of ?9-tetrahydrocannabinol, Cannabidiol and Metabolites in Blood following Vaporization and Oral Ingestion of Cannabidiol Merchandise. J Anal Toxicol 2022. View summary.
Birnbaum AK, Karanam A, Marino SE, et al. Meals impact on pharmacokinetics of cannabidiol oral capsules in grownup sufferers with refractory epilepsy. Epilepsia. 2019 Aug;60(8):1586-1592. View summary.
Bisogno T, Di Marzo Y. The position of the endocannabinoid system in Alzheimer’s illness: info and hypotheses. Curr Pharm Des 2008;14(23):2299-3305. View summary.
Bloomfield MAP, Inexperienced SF, Hindocha C, et al. The consequences of acute cannabidiol on cerebral blood stream and its relationship to reminiscence: An arterial spin labelling magnetic resonance imaging research. J Psychopharmacol. 2020;34(9):981-989. View summary.
Bloomfield MAP, Yamamori Y, Hindocha C, et al. The acute results of cannabidiol on emotional processing and nervousness: a neurocognitive imaging research. Psychopharmacology (Berl) 2022. View summary.
Bolsoni LM, Crippa JAS, Hallak JEC, Guimarães FS, Zuardi AW. Results of cannabidiol on signs induced by the recall of traumatic occasions in sufferers with posttraumatic stress dysfunction. Psychopharmacology (Berl) 2022. View summary.
Bonn-Miller MO, Loflin MJE, Thomas BF, Marcu JP, Hyke T, Vandrey R. Labeling accuracy of cannabidiol extracts bought on-line. JAMA 2017 Nov;318(17):1708-9. View summary.
Booz GW. Cannabidiol as an emergent therapeutic technique for lessening the impression of irritation on oxidative stress. Free Radic Biol Med 2011;51(5):1054-61. View summary.
Bornheim LM, Everhart ET, Li J, Correia MA. Characterization of cannabidiol-mediated cytochrome P450 inactivation. Biochem Pharmacol 1993;45(6):1323-31. View summary.
Brady CM, DasGupta R, Dalton C, et al. An open-label research of cannabis-based extracts for bladder dysfuntion in superior a number of sclerosis. Mult Scler 2004;10(4):425-33. View summary.
Campos AC, Guimaraes FS. Activation of 5HT1A receptors mediates the anxiolytic results of cannabidiol in a PTSD mannequin. Behav Pharmacol 2009;20:S54.
Campos AC, Moreira FA, Gomes FV, et al. A number of mechanisms concerned within the large-spectrum therapeutic potential of cannabidiol in psychiatric issues. Philos Trans R Soc Lond B Biol Sci 2012;367(1607):3364-78. View summary.
Cannabidiol Now Exhibiting Up In Dietary Dietary supplements. Pure Medicines Web page. (Accessed Could 31, 2015).
Capano A, Weaver R, Burkman E. Analysis of the results of CBD hemp extract on opioid use and high quality of life indicators in persistent ache sufferers: a potential cohort research. Postgrad Med. 2020;132(1):56-61. View summary.
Carlini EA, Cunha JM. Hypnotic and antiepileptic results of cannabidiol. J Clin Pharmacol 1981;21(8-9 Suppl):417S-27S. View summary.
Carlini EA, Leite JR, Tannhauser M, Berardi AC. Letter: Cannabidiol and Hashish sativa extract shield mice and rats in opposition to convulsive brokers. J Pharm Pharmacol 1973;25(8):664-5. View summary.
Carmona-Hidalgo B, García-Martín A, Muñoz E, González-Mariscal I. Detrimental Impact of Cannabidiol on the Early Onset of Diabetic Nephropathy in Male Mice. Prescribed drugs (Basel) 2021;14(9):863. View summary.
Carroll CB, Bain PG, Teare L, et al. Hashish for dyskinesia in Parkinson illness: a randomized double-blind crossover research. Neurology 2004;63(7):1245-50. View summary.
Carvalho RK, Rocha TL, Fernandes FH, et al. Reducing sperm high quality in mice subjected to persistent cannabidiol publicity: New insights of cannabidiol-mediated male reproductive toxicity. Chem Biol Work together 2022;351:109743. View summary.
Casarotto PC, Gomes FV, Resstel LB, Guimaraes FS. Cannabidiol inhibitory impact on marble-burying conduct: involvement of CB1 receptors. Behav Pharmacol 2010;21(4):353-8. View summary.
Chesney E, Oliver D, Inexperienced A, et al. Hostile results of cannabidiol: a scientific assessment and meta-analysis of randomized scientific trials. Neuropsychopharmacology. 2020. View summary.
Cochrane-Snyman KC, Cruz C, Morales J, Coles M. The Results of Cannabidiol Oil on Noninvasive Measures of Muscle Harm in Males. Med Sci Sports activities Exerc. 2021. View summary.
Cole TB, Saitz R. Hashish and Impaired Driving. JAMA. 2020;324(21):2163-2164. View summary.
Consroe P, Sandyk R, Snider SR. Open label analysis of cannabidiol in dystonic motion issues. Int J Neurosci 1986;30(4):277-82. View summary.
Consroe P, Wolkin A. Cannabidiol-antiepilpetic drug comparisons and interactions in experimentally induced seizures in rats. J Pharmacol Exp Ther 1977;201(1):26-32. View summary.
Consroe PF, Wokin AL. Anticonvulsant interplay of cannabidiol and ethosuximide in rats. J Pharm Pharmacol 1977;29(8):500-1. View summary.
Cortopassi J. Warfarin dose adjustment required after cannabidiol initiation and titration. Am J Well being Syst Pharm. 2020;77(22):1846-1851. View summary.
Sofa DG, Prepare dinner H, Ortori C, Barrett D, Lund JN, O’Sullivan SE. Palmitoylethanolamide and Cannabidiol Stop Irritation-induced Hyperpermeability of the Human Intestine In Vitro and In Vivo-A Randomized, Placebo-controlled, Double-blind Managed Trial. Inflamm Bowel Dis. 2019;25(6):1006-1018. View summary.
Covington TR, et al. Handbook of Nonprescription Medicine. eleventh ed. Washington, DC: American Pharmaceutical Affiliation, 1996.
Crippa JA, Derenusson GN, Ferrari TB, et al. Neural foundation of anxiolytic results of cannabidiol (CBD) in generalized social nervousness dysfunction: a preliminary report. J Psychopharmacol 2011;25(1):121-30. View summary.
Crippa JAS, Pacheco JC, Zuardi AW, et al. Cannabidiol for COVID-19 Sufferers with Delicate to Reasonable Signs (CANDIDATE Research): A Randomized, Double-Blind, Placebo-Managed Scientific Trial. Hashish Cannabinoid Res 2021. View summary.
Crippa JAS, Zuardi AW, Guimarães FS, et al. Burnout and Misery Prevention With Cannabidiol in Entrance-line Well being Care Employees Dealing With COVID-19 (BONSAI) Trial Investigators. Efficacy and Security of Cannabidiol Plus Commonplace Care vs Commonplace Care Alone for the Remedy of Emotional Exhaustion and Burnout Amongst Frontline Well being Care Employees Through the COVID-19 Pandemic: A Randomized Scientific Trial. JAMA Netw Open. 2021 Aug 2;4(8):e2120603. View summary.
Crockett J, Critchley D, Tayo B, Berwaerts J, Morrison G. A section 1, randomized, pharmacokinetic trial of the impact of various meal compositions, entire milk, and alcohol on cannabidiol publicity and security in wholesome topics. Epilepsia. 2020;61(2):267-277. View summary.
Cryan JF, Markou A, Lucki I. Assessing antidepressant exercise in rodents: current developments and future wants. Traits Pharmacol Sci 2002;23(5):238-45. View summary.
Czégény Z, Nagy G, Babinszki B, et al. CBD, a precursor of THC in e-cigarettes. Sci Rep 2021;11(1):8951. View summary.
Dalton WS, Martz R, Lemberger L, et al. Affect of cannabidiol on delta-9-tetrahydrocannabinol results. Clin Pharmacol Ther 1976;19(3):300-9. View summary.
Darweesh RS, Khamis TN, El-Elimat T. The impact of cannabidiol on the pharmacokinetics of carbamazepine in rats. Naunyn Schmiedebergs Arch Pharmacol. 2020. View summary.
Davis BH, Beasley TM, Amaral M, et al. Pharmacogenetic Predictors of Cannabidiol Response and Tolerability in Remedy-Resistant Epilepsy. Clin Pharmacol Ther 2021;110(5):1368-1380. View summary.
de Almeida CMO, Brito MMC, Bosaipo NB, et al. Cannabidiol for Speedy Eye Motion Sleep Habits Dysfunction. Mov Disord. 2021. View summary.
de Carvalho Reis R, Almeida KJ, da Silva Lopes L, de Melo Mendes CM, Bor-Seng-Shu E. Efficacy and opposed occasion profile of cannabidiol and medicinal hashish for treatment-resistant epilepsy: Systematic assessment and meta-analysis. Epilepsy Behav. 2020;102:106635. View summary.
de Faria SM, de Morais Fabrício D, Tumas V, et al. Results of acute cannabidiol administration on nervousness and tremors induced by a Simulated Public Talking Check in sufferers with Parkinson’s illness. J Psychopharmacol. 2020 Jan 7:269881119895536. View summary.
De Filippis D, Esposito G, Cirillo C, et al. Cannabidiol reduces intestinal irritation by means of the management of neuroimmune axis. PLoS One 2011;6(12):e28159. View summary.
Devinsky O, Cilio MR, Cross H, et al. Cannabidiol: pharmacology and potential therapeutic position in epilepsy and different neuropsychiatric issues. Epilepsia 2014;55(6):791-802. View summary.
Devinsky O, Cross JH, Laux L, et al. Trial of cannabidiol for drug-resistant seizures within the Dravet Syndrome. N Engl J Med. 2017 Could 25;376(21):2011-2020. View summary.
Devinsky O, Kraft Ok, Rusch L, Fein M, Leone-Bay A. Improved Bioavailability with Dry Powder Cannabidiol Inhalation: A Part 1 Scientific Research. J Pharm Sci 2021. View summary.
Devinsky O, Marsh E, Friedman D, et la. Cannabidiol in sufferers with treatment-resistant epilepsy: an open-label interventional trial. Lancet Neurol. 2016 Mar;15(3):270-8. View summary.
Devinsky O, Patel AD, Cross JH, et al. Impact of Cannabidiol on Drop Seizures within the Lennox-Gastaut Syndrome. N Engl J Med. 2018 Could 17;378(20):1888-1897. View summary.
Devinsky O, Verducci C, Thiele EA, et al. Open-label use of extremely purified CBD (Epidiolex®) in sufferers with CDKL5 deficiency dysfunction and Aicardi, Dup15q, and Doose syndromes. Epilepsy Behav. 2018 Sep;86:131-137. Epub 2018 Jul 11. View summary.
Dieterle M, Zurbriggen L, Mauermann E, et al. Ache response to cannabidiol in opioid-induced hyperalgesia, acute nociceptive ache, and allodynia utilizing a mannequin mimicking acute ache in wholesome adults in a randomized trial (CANAB II). Ache 2022. View summary.
Drug Enforcement Administration, Division of Justice. Schedules of Managed Substances: Placement in Schedule V of Sure FDA-Permitted Medicine Containing Cannabidiol; Corresponding Change to Allow Necessities. Remaining order. Fed Regist. 2018 Sep 28;83(189):48950-3. View summary.
Ebrahimi-Fakhari D, Agricola KD, Tudor C, Krueger D, Franz DN. Cannabidiol Elevates Mechanistic Goal of Rapamycin Inhibitor Ranges in Sufferers With Tuberous Sclerosis Advanced. Pediatr Neurol. 2020;105:59-61. View summary.
El-Alfy AT, Ivey Ok, Robinson Ok, et al. Antidepressant-like impact of delta9-tetrahydrocannabinol and different cannabinoids remoted from Hashish sativa L. Pharmacol Biochem Behav 2010;95(4):434-42. View summary.
El-Remessy AB, Al-Shabrawey M, Khalifa Y, et al. Neuroprotective and blood-retinal barrier-preserving results of cannabidiol in experimental diabetes. Am J Pathol 2006;168(1):235-44. View summary.
Englund A, Morrison PD, Nottage J, et al. Cannabidiol inhibits THC-elicited paranoid signs and hippocampal-dependent reminiscence impairment. J Psychopharmacol 2013;27(1):19-27. View summary.
Epidiolex (cannabidiol) prescribing info. Greenwich Biosciences, Inc., Carlsbad, CA, 2019. Obtainable at: (accessed 5/9/2019)
Esposito G, De Filippis D, Maiuri MC, et al. Cannabidiol inhibits inducible nitric oxide synthase protein expression and nitric oxide manufacturing in beta-amyloid stimulated PC12 neurons by means of p38 MAP kinase and NF-kappaB involvement. Neurosci Lett 2006;399(1-2):91-5. View summary.
Esposito G, Scuderi C, Savani C, et al. Cannabidiol in vivo blunts beta-amyloid induced neuroinflammation by suppressing IL-1beta and iNOS expression. Br J Pharmacol 2007;151(8):1272-9. View summary.
FDA Client Updates: What You Ought to Know About Utilizing Hashish, Together with CBD, When Pregnant or Breastfeeding. U. S. Meals and Drug Administration (FDA). October 2019. Obtainable at:
Formukong EA, Evans AT, Evans FJ. Analgesic and anti inflammatory exercise of constituents of Hashish sativa L. Irritation 1988;12(4):361-71. View summary.
Freeman TP, Hindocha C, Baio G, et al. Cannabidiol for the therapy of hashish use dysfunction: a section 2a, double-blind, placebo-controlled, randomised, adaptive Bayesian trial. Lancet Psychiatry. 2020; 7(10):865-874. View summary.
Fusar-Poli P, Allen P, Bhattacharyya S, et al. Modulation of efficient connectivity throughout emotional processing by Delta 9-tetrahydrocannabinol and cannabidiol. Int J Neuropsychopharmacol 2010;13(4):421-32. View summary.
Gaston TE, Ampah SB, Martina Bebin E, et al. Lengthy-term security and efficacy of extremely purified cannabidiol for therapy refractory epilepsy. Epilepsy Behav. 2021;117:107862. View summary.
Gaston TE, Bebin EM, Cutter GR, Liu Y, Szaflarski JP; UAB CBD Program. Interactions between cannabidiol and generally used antiepileptic medication. Epilepsia. 2017 Sep;58(9):1586-92. View summary.
Geffrey AL, Pollack SF, Bruno PL, Thiele EA. Drug-drug interplay between clobazam and cannabidiol in kids with refractory epilepsy. Epilepsia. 2015 Aug;56(8):1246-51. View summary.
Gofshteyn JS, Wilfong A, Devinsky O, et al. Cannabidiol as a possible therapy for febrile infection-related epilepsy syndrome (FIRES) within the acute and persistent phases. J Little one Neurol. 2017 Jan;32(1):35-40. View summary.
Granjeiro EM, Gomes FV, Guimaraes FS, et al. Results of intracisternal administration of cannabidiol on the cardiovascular and behavioral responses to acute restraint stress. Pharmacol Biochem Behav 2011;99(4):743-8. View summary.
Guimaraes FS, Chairetti TM, Graeff FG, Zuardi AW. Antianxiety impact of cannabidiol within the elevated plus-maze. Psychopharmacology (Berl) 1990;100(4):558-9. View summary.
Guimaraes VM, Zuardi AW, Del Bel EA, Guimaraes FS. Cannabidiol will increase Fos expression within the nucleus accumbens however not within the dorsal striatum. Life Sci 2004;75(5):633-8. View summary.
Gurley BJ, Murphy TP, Gul W, Walker LA, ElSohly M. Content material versus Label Claims in Cannabidiol (CBD)-Containing Merchandise Obtained from Industrial Shops within the State of Mississippi. J Food plan Suppl. 2020;17(5):599-607. View summary.
Hacke ACM, Lima D, de Costa F, et al. Probing the antioxidant exercise of [delta](9)-tetrahydrocannabinol and cannabidiol in Hashish sativa extracts. Analyst. 2019;144(16):4952-4961. View summary.
Haffar A, Khan IA, Abdelaal MS, Banerjee S, Sharkey PF, Lonner JH. Topical Cannabidiol (CBD) After Whole Knee Arthroplasty Does Not Lower Ache or Opioid Use: A Potential Randomized Double-Blinded Placebo-Managed Trial. J Arthroplasty 2022. View summary.
Hampson AJ, Grimaldi M, Axelrod J, Wink D. Cannabidiol and (-)Delta9-tetrahydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci U S A. 1998;95(14):8268-73. View summary.
Harris HM, Gul W, ElSohly MA, Sufka KJ. Differential Results of Cannabidiol and a Novel Cannabidiol Analog on Oxycodone Place Choice and Analgesia in Mice: an Opioid Abuse Deterrent with Analgesic Properties. Hashish Cannabinoid Res 2021. View summary.
Harvey DJ. Absorption, distribution, and biotransformation of the cannabinoids. Marijuana and Drugs. 1999;91-103.
Hazekamp A. The difficulty with CBD oil. Med Hashish Cannabinoids. 2018 Jun;1:65-72.
Hess EJ, Moody KA, Geffrey AL, et al. Cannabidiol as a brand new therapy for drug-resistant epilepsy in tuberous sclerosis advanced. Epilepsia. 2016 Oct;57(10):1617-24.View summary.
Heussler H, Cohen J, Silove N, et al. A section 1/2, open-label evaluation of the security, tolerability, and efficacy of transdermal cannabidiol (ZYN002) for the therapy of pediatric fragile X syndrome. J Neurodev Disord. 2019;11(1):16. View summary.
Hobbs JM, Vazquez AR, Remijan ND, et al. Analysis of pharmacokinetics and acute anti-inflammatory potential of two oral cannabidiol preparations in wholesome adults. Phytother Res. 2020;34(7):1696-1703. View summary.
Hosseini A, McLachlan AJ, Lickliter JD. A section I trial of the security, tolerability and pharmacokinetics of cannabidiol administered as single-dose oil resolution and single and a number of doses of a sublingual wafer in wholesome volunteers. Br J Clin Pharmacol. 2020. View summary.
Hotz J, Fehlmann B, Papassotiropoulos A, de Quervain DJ, Schicktanz NS. Cannabidiol enhances verbal episodic reminiscence in wholesome younger contributors: A randomized scientific trial. J Psychiatr Res 2021;143:327-333. View summary.
Hurd YL, Spriggs S, Alishayev J, et al. Cannabidiol for the Discount of Cue-Induced Craving and Nervousness in Drug-Abstinent People With Heroin Use Dysfunction: A Double-Blind Randomized Placebo-Managed Trial. Am J Psychiatry. 2019:appiajp201918101191. View summary.
Hussain SA, Dlugos DJ, Cilio MR, Parikh N, Oh A, Sankar R. Artificial pharmaceutical grade cannabidiol for therapy of refractory childish spasms: A multicenter phase-2 research. Epilepsy Behav. 2020 Jan;102:106826. View summary.
Isenmann E, Veit S, Starke L, Flenker U, Diel P. Results of Cannabidiol Supplementation on Skeletal Muscle Regeneration after Intensive Resistance Coaching. Vitamins 2021;13(9):3028. View summary.
Iuvone T, Esposito G, De Filippis D, et al. Cannabidiol: a promising new drug for neurodegenerative issues? CNS Neurosci Ther 2009;15(1):65-75. View summary.
Izgelov D, Davidson E, Barasch D, Regev A, Domb AJ, Hoffman A. Pharmacokinetic investigation of artificial cannabidiol oral formulations in wholesome volunteers. Eur J Pharm Biopharm. 2020;154:108-115. View summary.
Izzo AA, Borelli F, Capasso R, et al. Non-psychotropic plant cannabinoids: new therapeutic alternatives from an historical herb. Traits Pharmacol Sci 2009;30(10):515-27. View summary.
Jacobsson SO, Rongard E, Stridh M, et al. Serum-dependent results of tamoxifen and cannabinoids upon C6 glioma cell viability. Biochem Pharmacol 2000;60(12):1807-13. View summary.
Jones É, Vlachou S. Cannabidiol Does Not Trigger Vital Modifications to Working Reminiscence Efficiency within the N-Again Process. Prescribed drugs (Basel) 2021;14(11):1165. View summary.
Kaplan EH, Offermann EA, Sievers JW, Comi AM. Cannabidiol therapy for refractory seizures in Sturge-Weber Syndrome. Pediatr Neurol. 2017 Jun;71:18-23.e2. View summary.
Karler R, Cely W, Turkanis SA. The anticonvulsant exercise of cannabidiol and cannabinol. Life Sci 1973;13(11):1527-31. View summary.
Karler R, Turkanis SA. Subacute cannabinoid therapy: anticonvulsant exercise and withdrawal excitability in mice. Br J Pharmacol 1980;68(3):479-84. View summary.
Karoly HC, Mueller RL, Andrade CC, Hutchison KE. THC and CBD results on alcohol use amongst alcohol and hashish co-users. Psychol Addict Behav. 2021. View summary.
Kaufmann R, Aqua Ok, Lombardo J, Lee M. Noticed Influence of Lengthy-term Consumption of Oral Cannabidiol on Liver Perform in Wholesome Adults. Hashish Cannabinoid Res 2021. View summary.
Kavia RB, De Ridder D, Constantinescu CS, et al. Randomized managed trial of Sativex to deal with detrusor overactivity in a number of sclerosis. Mult Scler 2010;16(11):1349-59. View summary.
Klotz KA, Grob D, Hirsch M, Metternich B, Schulze-Bonhage A, Jacobs J. Efficacy and Tolerance of Artificial Cannabidiol for Remedy of Drug Resistant Epilepsy. Entrance Neurol. 2019 Dec 10;10:1313. View summary.
Klotz KA, Grob D, Schönberger J, et al. Impact of Cannabidiol on Interictal Epileptiform Exercise and Sleep Structure in Kids with Intractable Epilepsy: A Potential Open-Label Research. CNS Medicine 2021;35(11):1207-1215. View summary.
Klotz KA, Hirsch M, Heers M, Schulze-Bonhage A, Jacobs J. Results of cannabidiol on brivaracetam plasma ranges. Epilepsia. 2019;60(7):e74-e77. View summary.
Knaub Ok, Sartorius T, Dharsono T, Wacker R, Wilhelm M, Schön C. A Novel Self-Emulsifying Drug Supply System (SEDDS) Based mostly on VESIsorb Formulation Know-how Enhancing the Oral Bioavailability of Cannabidiol in Wholesome Topics. Molecules. 2019;24(16). pii: E2967. View summary.
Köck P, Lang E, Trulley VN, et al. Cannabidiol Cigarettes as Adjunctive Remedy for Psychotic Problems – A Randomized, Open-Label Pilot-Research. Entrance Psychiatry 2021;12:736822. View summary.
Lattanzi S, Trinka E, Striano P, et al. Cannabidiol efficacy and clobazam standing: A scientific assessment and meta-analysis. Epilepsia. 2020;61(6):1090-1098. View summary.
Laux LC, Bebin EM, Checketts D, et al. Lengthy-term security and efficacy of cannabidiol in kids and adults with therapy resistant Lennox-Gastaut syndrome or Dravet syndrome: Expanded entry program outcomes. Epilepsy Res. 2019;154:13-20. View summary.
Lee CY, Wey SP, Liao MH, et al. A comparative research on cannabidiol-induced apoptosis in murine thymocytes and EL-4 thymoma cells. Int Immunopharmacol 2008;8(5):732-40. View summary.
Leehey MA, Liu Y, Hart F, et al. Security and Tolerability of Cannabidiol in Parkinson Illness: An Open Label, Dose-Escalation Research. Hashish Cannabinoid Res. 2020;5(4):326-336. View summary.
Leighty EG, Fentiman AF Jr, Foltz RL. Lengthy-retained metabolites of delta9- and delta8-tetrahydrocannabinols recognized as novel fatty acid conjugates. Res Commun Chem Pathol Pharmacol 1976;14(1):13-28. View summary.
Leino AD, Emoto C, Fukuda T, Privitera M, Vinks AA, Alloway RR. Proof of a clinically important drug-drug interplay between cannabidiol and tacrolimus. Am J Transplant. 2019;19(10):2944-2948. View summary.
Leweke FM, Kranaster L, Pahlisch F, et al. The efficacy of cannabidiol within the therapy of schizophrenia – a translational strategy. Schizophr Bull 2011;37(Suppl 1):313.
Leweke FM, Piomelli D, Pahlisch F, et al. Cannabidiol enhances anandamide signaling and alleviates psychotic signs of schizophrenia. Transl Psychiatry 2012;2:e94. View summary.
Leweke FM, Rohleder C, Gerth CW, Hellmich M, Pukrop R, Koethe D. Cannabidiol and Amisulpride Enhance Cognition in Acute Schizophrenia in an Explorative, Double-Blind, Energetic-Managed, Randomized Scientific Trial. Entrance Pharmacol. 2021;12:614811. View summary.
Ligresti A, Moriello AS, Starowicz Ok, et al. Antitumor exercise of plant cannabinoids with emphasis on the impact of cannabidiol on human breast carcinoma. J Pharmacol Exp Ther 2006;318(3):1375-87. View summary.
Linares IM, Zuardi AW, Pereira LC, et al. Cannabidiol presents an inverted U-shaped dose-response curve in a simulated public talking check. Braz J Psychiatry. 2019 Jan-Feb;41(1):9-14. Epub 2018 Oct 11. View summary.
Lengthy LE, Chesworth R, Huang XF, et al. A behavioral comparability of acute and persistent Delta9-tetrahydrocannabinol and cannabidiol in C57BL/6JArc mice. Int J Neuropsychopharmacol 2010;13(7):861-76. View summary.
Lopez HL, Cesareo KR, Raub B, et al. Results of hemp extract on markers of wellness, stress resilience, restoration and scientific biomarkers of security in obese, however in any other case wholesome topics. J Food plan Suppl. 2020;17(5):561-86. View abstracts.
Madan Cohen J, Checketts D, Dunayevich E, et al. Time to onset of cannabidiol therapy results in Dravet syndrome: Evaluation from two randomized managed trials. Epilepsia 2021;62(9):2218-2227. View summary.
Madden Ok, Tanco Ok, Bruera E. Clinically Vital Drug-Drug Interplay Between Methadone and Cannabidiol. Pediatrics. 2020;e20193256. View summary.
Magen I, Avraham Y, Ackerman Z, et al. Cannabidiol ameliorates cognitive and motor impairments in mice with bile duct ligation. J Hepatol 2009;51(3):528-34. View summary.
Maghfour J, Rundle CW, Rietcheck HR, et al. Assessing the results of topical cannabidiol in sufferers with atopic dermatitis. Dermatol On-line J. 2021;27(2):13030/qt8h50k2vs. View summary.
Malfait AM, Gallily R, Sumariwalla PF, et al. The non-psychoactive cannabis-constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc Natl Acad Sci USA 2000;97:9561-6. View summary.
Malone DT, Jongejan D, Taylor DA. Cannabidiol reverses the discount in social interplay produced by low dose Delta(9)-tetrahydrocannabinol in rats. Pharmacol Biochem Behav 2009;93(2):91-6. View summary.
Martin RC, Gaston TE, Thompson M, et al. Cognitive functioning following long-term cannabidiol use in adults with treatment-resistant epilepsy. Epilepsy Behav. 2019;97:105-110. View summary.
Masataka N. Anxiolytic Results of Repeated Cannabidiol Remedy in Youngsters With Social Nervousness Problems. Entrance Psychol. 2019 Nov 8;10:2466. View summary.
Massi P, Solinas M, Cinquina V, Parolaro D. Cannabidiol as a possible anticancer drug. Br J Clin Pharmacol 2013;75(2):303-12. View summary.
Massi P, Valenti M, Vaccani A, et al. 5-Lipoxygenase and anandamide hydrolase (FAAH) mediate the antitumor exercise of cannabidiol, a non-psychoactive cannabinoid. J Neurochem 2008;104(4):1091-100. View summary.
Masterson D. CBD from orange peels: A unique CBD story. August 3, 2021. Obtainable at: Accessed October 26, 2021.
McAllister SD, Christian RT, Horowitz MP, et al. Cannabidiol as a novel inhibitor of Id-1 gene expression in aggressive breast most cancers cells. Mol Most cancers Ther 2007;6(11):2921-7. View summary.
McAllister SD, Murase R, Christian RT, et al. Pathways mediating the results of cannabidiol on the discount of breast most cancers cell proliferation, invasion, and metastasis. Breast Most cancers Res Deal with 2011;129(1):37-47. View summary.
McGuire P, Robson P, Cubala WJ, et al. Cannabidiol (CBD) as an Adjunctive Remedy in Schizophrenia: A Multicenter Randomized Managed Trial.Am J Psychiatry. 2018;175(3):225-231. View summary.
McNamara NA, Dang LT, Sturza J, et al. Thrombocytopenia in pediatric sufferers on concurrent cannabidiol and valproic acid. Epilepsia. 2020. View summary.
Miller I, Scheffer IE, Gunning B, et al. Dose-Ranging Impact of Adjunctive Oral Cannabidiol vs Placebo on Convulsive Seizure Frequency in Dravet Syndrome: A Randomized Scientific Trial. JAMA Neurol. 2020;77(5):613-621. View summary.
Miller OS, Elder EJ Jr, Jones KJ, Gidal BE. Evaluation of cannabidiol (CBD) and THC in nonprescription shopper merchandise: Implications for sufferers and practitioners. Epilepsy Behav 2022;127:108514. View summary.
Mongeau-Pérusse V, Rizkallah E, Morissette F, et al. Cannabidiol Impact on Nervousness Signs and Stress Response in People With Cocaine Use Dysfunction: Exploratory Outcomes From a Randomized Managed Trial. J Addict Med 2022. View summary.
Monti JM. Hypnoticlike results of cannabidiol within the rat. Psychopharmacology (Berl) 1977;55(3):263-5. View summary.
Moreira FA, Aguiar DC, Guimaraes FS. Anxiolytic-like impact of cannabidiol within the rat Vogel battle check. Prog Neuropsychopharmacol Biol Psychiatry 2006;30(8):1466-71. View summary.
Moreira FA, Guimaraes FS. Cannabidiol inhibits the hyperlocomotion induced by psychomimetic medication in mice. Eur J Pharmacol 2005;512(2-3):199-205. View summary.
Morgan CJ, Das RK, Joye A, et al. Cannabidiol reduces cigarette consumption in tobacco people who smoke: preliminary findings. Addict Behav 2013;38(9):2433-6. View summary.
Morrison G, Crockett J, Blakey G, Sommerville Ok. A Part 1, Open-Label, Pharmacokinetic Trial to Examine Potential Drug-Drug Interactions Between Clobazam, Stiripentol, or Valproate and Cannabidiol in Wholesome Topics. Clin Pharmacol Drug Dev. 2019;8(8):1009-1031. View summary.
Murillo-Rodriguez E, Millan-Aldaco D, Palomero-Rivero M, et al. Cannabidiol, a constituent of Hashish sativa, modulates sleep in rats. FEBS Lett 2006;580(18):4337-45. View summary.
Naftali T, Mechulam R, Marii A, et al. Low-dose cannabidiol is protected however not efficient within the therapy of Crohn’s Illness, a randomized managed trial. Dig Dis Sci. 2017 Jun;62(6):1615-20. View summary.
Nasrin S, Watson CJW, Perez-Paramo YX, Lazarus P. Cannabinoid Metabolites as Inhibitors of Main Hepatic CYP450 Enzymes, with Implications for Hashish-Drug Interactions. Drug Metab Dispos 2021;49(12):1070-1080. View summary.
Nguyen LC, Yang D, Nicolaescu V, et al. Cannabidiol inhibits SARS-CoV-2 replication by means of induction of the host ER stress and innate immune responses. Sci Adv 2022. View summary.
Nitecka-Buchta A, Nowak-Wachol A, Wachol Ok, et al. Myorelaxant Impact of Transdermal Cannabidiol Utility in Sufferers with TMD: A Randomized, Double-Blind Trial. J Clin Med. 2019 Nov 6;8(11). pii: E1886. View summary.
Notcutt W, Langford R, Davies P, et al. A placebo-controlled, parallel group, randomized withdrawal research of topics with signs of spasticity as a result of a number of sclerosis who’re receiving long-term Sativex (nabiximols). Mult Scler 2012;18(2):219-28. View summary.
Novotna A, Mares J, Ratcliffe S, et al. A randomized, double-blind, placebo-controlled, parallel-group, enriched-design research of nabiximols* (Sativex), as add-on remedy, in topics with refractory spasticity trigger by a number of sclerosis. Eur J Neurol 2011;18(9):1122-31. View summary.
Onaivi ES, Inexperienced MR, Martin BR. Pharmacological characterization of cannabinoids within the elevated plus maze. J Pharmacol Exp Ther 1990;253(3):1002-9. View summary.
Oruganti P, Betcher S, Wakade Z, Ding X, Abegunde AT. Cannabidiol Oil-Related Microscopic Colitis. Cureus. 2020;12(9):e10528. View summary.
Overview. GW Prescribed drugs Web page. Obtainable at: Accessed: Could 31, 2015.
Parihar V, Rogers A, Blain AM, Zacharias SRK, Patterson LL, Siyam MA. Discount in Tamoxifen Metabolites Endoxifen and N-desmethyltamoxifen With Persistent Administration of Low Dose Cannabidiol: A CYP3A4 and CYP2D6 Drug Interplay. J Pharm Pract. 2020:897190020972208. View summary.
Partridge Snow & Hahn LLP. FDA Refuses to Approve CBVD As a Meals Ingredient or Complement. August 19, 2021. Obtainable at: Accessed October 26, 2021.
Patel AD, Mazurkiewicz-Beldzinska M, Chin RF, et al. Lengthy-term security and efficacy of add-on cannabidiol in sufferers with Lennox-Gastaut syndrome: Outcomes of a long-term open-label extension trial. Epilepsia 2021;62(9):2228-2239. View summary.
Patrician A, Versic-Bratincevic M, Mijacika T, et al. Examination of a New Supply Method for Oral Cannabidiol in Wholesome Topics: A Randomized, Double-Blinded, Placebo-Managed Pharmacokinetics Research. Adv Ther. 2019. View summary.
Pavlovic R, Nenna G, Calvi L, et al. High quality Traits of “Cannabidiol Oils”: Cannabinoids Content material, Terpene Fingerprint and Oxidation Stability of European Commercially Obtainable Preparations. Molecules. 2018 Could 20;23(5). pii: E1230. View summary.
Pertwee RG. The varied CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delat9-tetrahydrocannabivarin. Br J Pharmacol 2008;153:199-215. View summary.
Pickens JT. Sedative exercise of hashish in relation to its delta’-trans-tetrahydrocannabinol and cannabidiol content material. Br J Pharmacol 1981;72(4):649-56. View summary.
Poklis JL, Mulder HA, Peace MR. The surprising identification of the cannabimimetic, 5F-ADB, and dextromethorphan in commercially obtainable cannabidiol e-liquids. Forensic Sci Int. 2019 Jan;294:e25-e27. Epub 2018 Nov 1. View summary.
Pretzsch CM, Freyberg J, Voinescu B, et al. Results of cannabidiol on mind excitation and inhibition techniques; a randomised placebo-controlled single dose trial throughout magnetic resonance spectroscopy in adults with and with out autism spectrum dysfunction. Neuropsychopharmacology. 2019;44(8):1398-1405. View summary.
Pretzsch CM, Voinescu B, Mendez MA, et al. The impact of cannabidiol (CBD) on low-frequency exercise and purposeful connectivity within the mind of adults with and with out autism spectrum dysfunction (ASD). J Psychopharmacol. 2019:269881119858306. View summary.
Product info for Marinol. AbbVie. North Chicago, IL 60064. August 2017. Obtainable at:
Rajesh M, Mukhopadhyay P, Batkai S, et al. Cannabidiol attenuates cardiac dysfunction, oxidative stress, fibrosis, and inflammatory and cell dying signaling pathways in diabetic cardiomyopathy. J Am Coll Cardiol 2010;56(25):2115-25. View summary.
Rajesh M, Mukhopadhyay P, Batkai S, et al. Cannabidiol attenuates excessive glucose-induces endothelial cell inflammatory response and barrier disruption. Am J Physiol Coronary heart Circ Physiol 2007;293(1):H610-H619. View summary.
Resstel LB, Joca SR, Moreira FA, et al. Results of cannabidiol and diazepam on behavioral and cardiovascular responses induced by contextual conditioned worry in rats. Behav Mind Res 2006;172(2):294-8. View summary.
Resstel LB, Tavares RF, Lisboa SF, et al. 5-HT1A receptors are concerned within the cannabidiol-induced attenuation of behavioral and cardiovascular responses to acute stress in rats. Br J Pharmacol 2009;156(1):181-8. View summary.
Rianprakaisang T, Gerona R, Hendrickson RG. Industrial cannabidiol oil contaminated with the artificial cannabinoid AB-FUBINACA given to a pediatric affected person. Clin Toxicol (Phila). 2020;58(3):215-216. View summary.
Sahinovic A, Irwin C, Doohan PT, et al. Results of Cannabidiol on Train Physiology and Bioenergetics: A Randomised Managed Pilot Trial. Sports activities Med Open 2022;8(1):27. View summary.
Samara E, Bialer M, Mechoulam R. Pharmacokinetics of cannabidiol in canines. Drug Metab Dispos 1988;16(3):469-72. View summary.
Santos de Alencar S, Crippa JAS, Brito MCM, Pimentel ÂV, Cecilio Hallak JE, Tumas V. A single oral dose of cannabidiol didn’t cut back higher limb tremor in sufferers with important tremor. Parkinsonism Relat Disord. 2021;83:37-40. View summary.
Scheffer IE, Halford JJ, Miller I, et al. Add-on cannabidiol in sufferers with Dravet syndrome: Outcomes of a long-term open-label extension trial. Epilepsia 2021;62(10):2505-2517. View summary.
Scheffer IE, Hulihan J, Messenheimer J, et al. Security and Tolerability of Transdermal Cannabidiol Gel in Kids With Developmental and Epileptic Encephalopathies: A Nonrandomized Managed Trial. JAMA Netw Open 2021;4(9):e2123930. View summary.
Schneider T, Zurbriggen L, Dieterle M, et al. Ache response to cannabidiol in induced acute nociceptive ache, allodynia, and hyperalgesia through the use of a mannequin mimicking acute ache in wholesome adults in a randomized trial (CANAB I). Ache. 2021. doi: 10.1097/j.ache.0000000000002310. View summary.
Schoedel KA, Szeto I, Setnik B, et al. Abuse potential evaluation of cannabidiol (CBD) in leisure polydrug customers: A randomized, double-blind, managed trial. Epilepsy Behav. 2018 Nov;88:162-171. doi: 10.1016/j.yebeh.2018.07.027. Epub 2018 Oct 2. View summary.
Schubart CD, Sommer IE, Fusar-Poli P, et al. Cannabidiol as a possible therapy for psychosis. Eur Neuropsychopharmacol 2014;24(1):51-64. View summary.
Schubart CD, Sommer IE, van Gastel WA, et al. Hashish with excessive cannabidiol content material is related to fewer psychotic experiences. Schizophr Res 2011;130(1-3):216-21. View summary.
Sepulveda DE, Morris DP, Raup-Konsavage WM, Solar D, Vrana KE, Graziane NM. Evaluating the Antinociceptive Efficacy of Cannabidiol Alone or in Mixture with Morphine Utilizing the Formalin Check in Male and Feminine Mice. Hashish Cannabinoid Res 2021. View summary.
Serpell MG, Notcutt W, Collin C. Sativex long-term use: an open-label trial in sufferers with spasticity as a result of a number of sclerosis. J Neurol 2013;260(1):285-95. View summary.
Shrivastava A, Kuzontkoski PM, Groopman JE, Prasad A. Cannabidiol induces programmed cell dying in breast most cancers cells by coordinating the cross-talk between apoptosis and autophagy. Mol Most cancers Ther 2011;10(7):1161-72. View summary.
Singh RK, Dillon B, Tatum DA, Van Poppel KC, Bonthius DJ. Drug-Drug Interactions Between Cannabidiol and Lithium. Little one Neurol Open. 2020;7:2329048X20947896. View summary.
Spinella TC, Stewart SH, Naugler J, Yakovenko I, Barrett SP. Evaluating cannabidiol (CBD) expectancy results on acute stress and nervousness in wholesome adults: a randomized crossover research. Psychopharmacology (Berl). 2021. View summary.
Assertion from FDA Commissioner Scot Gottlieb, M.D., on signing of the Agriculture Enchancment Act and the company’s regulation of merchandise containing hashish and cannabis-derived compounds. U.S. Meals and Drug Administration Web page. Obtainable at: (Accessed Could 7, 2019).
Szaflarski JP, Bebin EM, Cutter G, DeWolfe J, et al. Cannabidiol improves frequency and severity of seizures and reduces opposed occasions in an open-label add-on potential research. Epilepsy Behav. 2018 Oct;87:131-136. Epub 2018 Aug 9. View summary.
Szaflarski JP, Hernando Ok, Bebin EM, et al. Greater cannabidiol plasma ranges are related to higher seizure response following therapy with a pharmaceutical grade cannabidiol. Epilepsy Behav. 2019;95:131-136. View summary.
Taylor L, Crockett J, Tayo B, Checketts D, Sommerville Ok. Abrupt withdrawal of cannabidiol (CBD): A randomized trial. Epilepsy Behav. 2020;104(Pt A):106938. View summary.
Taylor L, Crockett J, Tayo B, Morrison G. A Part 1, Open-Label, Parallel-Group, Single-Dose Trial of the Pharmacokinetics and Security of Cannabidiol (CBD) in Topics With Delicate to Extreme Hepatic Impairment. J Clin Pharmacol. 2019;59(8):1110-1119. View summary.
Thai C, Tayo B, Critchley D. A Part 1 Open-Label, Fastened-Sequence Pharmacokinetic Drug Interplay Trial to Examine the Impact of Cannabidiol on the CYP1A2 Probe Caffeine in Wholesome Topics. Clin Pharmacol Drug Dev. 2021. View summary.
Thiele EA, Bebin EM, Bhathal H, et al. Add-On Cannabidiol Remedy for Drug-Resistant Seizures in Tuberous Sclerosis Advanced: A Placebo-Managed Randomized Scientific Trial. JAMA Neurol. 2020. View summary.
Thiele EA, Bebin EM, Filloux F, et al. Lengthy-term cannabidiol therapy for seizures in sufferers with tuberous sclerosis advanced: An open-label extension trial. Epilepsia 2021. View summary.
Thiele EA, Marsh ED, French JA, et al. Cannabidiol in sufferers with seizures related to Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled section 3 trial. Lancet. 2018 Mar 17;391(10125):1085-1096. View summary.
Torres S, Lorente M, Rodriguez-Fornes F, et al. A mixed preclinical remedy of cannabinoids and temozolomide in opposition to glioma. Mol Most cancers Ther 2011;10(1):90-103. View summary.
Toth CC, Jedrzejewski NM, Ellis CL, Frey WH. Cannabinoid-mediated modulation of neuropathic ache and microglial accumulation in a mannequin of murine sort 1 diabetic peripheral neuropathic ache. Mol Ache 2010;6:16. View summary.
Uribe-Marino A, Francisco A, Castiblanco-Urbina MA, et al. Anti-aversive results of cannabidiol on innate fear-induced behaviors evoked by an ethological mannequin of panic assaults primarily based on a prey vs the wild snake Epicrates cenchria crassus confrontation paradigm. Neuropsychopharmacology 2012;37(2):412-21. View summary.
Valenti M, Massi P, Bolognini D, et al. Cannabidiol, a non-psychoactive cannabinoid compound inhibits human glioma cell migration and invasiveness. thirty fourth Nationwide Congress of the Italian Society of Pharmacology 2009.
Valvassori SS, Elias G, de Souza B, et al. Results of cannabidiol on amphetamine-induced oxidative stress era in an animal mannequin of mania. J Psychopharmacol 2011;25(2):274-80. View summary.
van Orten-Luiten AB, de Roos NM, Majait S, Witteman BJM, Witkamp RF. Results of Cannabidiol Chewing Gum on Perceived Ache and Properly-Being of Irritable Bowel Syndrome Sufferers: A Placebo-Managed Crossover Exploratory Intervention Research with Symptom-Pushed Dosing. Hashish Cannabinoid Res. 2021. View summary.
Vela J, Dreyer L, Petersen KK, Lars AN, Duch KS, Kristensen S. Cannabidiol therapy in hand osteoarthritis and psoriatic arthritis: a randomized, double-blind placebo-controlled trial. Ache 2021. View summary.
Velayudhan L, McGoohan Ok, Bhattacharyya S. Security and tolerability of pure and artificial cannabinoids in adults aged over 50 years: A scientific assessment and meta-analysis. PLoS Med. 2021;18(3):e1003524. View summary.
Wade DT, Makela PM, Home H, et al. Lengthy-term use of a cannabis-based therapy in spasticity and different signs in a number of sclerosis. Mult Scler 2006;12(5):639-45. View summary.
Wang GS, Bourne DWA, Klawitter J, et al. Disposition of Oral Cannabidiol-Wealthy Hashish Extracts in Kids with Epilepsy. Clin Pharmacokinet. 2020. View summary.
Watkins PB, Church RJ, Li J, Knappertz V. Cannabidiol and Irregular Liver Chemistries in Wholesome Adults: Outcomes of a Part I Scientific Trial. Clin Pharmacol Ther. 2020. View summary.
Wiemer-Kruel A, Stiller B, Bast T. Cannabidiol Interacts Considerably with Everolimus-Report of a Affected person with Tuberous Sclerosis Advanced. Neuropediatrics. 2019. View summary.
Woelfl T, Rohleder C, Mueller JK, et al. Results of Cannabidiol and Delta-9-Tetrahydrocannabinol on Emotion, Cognition, and Consideration: A Double-Blind, Placebo-Managed, Randomized Experimental Trial in Wholesome Volunteers. Entrance Psychiatry. 2020;11:576877. View summary.
Xu DH, Cullen BD, Tang M, Fang Y. The Effectiveness of Topical Cannabidiol Oil in Symptomatic Reduction of Peripheral Neuropathy of the Decrease Extremities. Curr Pharm Biotechnol. 2019 Dec 1. View summary.
Yadav V, Bever C Jr, Bowen J, et al. Abstract of evidence-based guideline: complementary and various drugs in a number of sclerosis: report of the rule of thumb growth subcommittee of the American Academy of Neurology. Neurology. 2014;82(12):1083-92. View summary.
Yamaori S, Ebisawa J, Okushima Y, et al. Potent inhibition of human cytochrome P450 3A isoforms by cannabidiol: position of phenolic hydroxyl teams within the resorcinol moiety. Life Sci 2011;88(15-16):730-6. View summary.
Yamaori S, Kushihara M, Yamamoto I, Watanabe Ok. Characterization of main phytocannabinoids, cannabidiol and cannabinol, as isoform-selective potent inhibitors of human CYP1 enzymes. Biochem Pharmacol 2010;79(11):1691-8. View summary.
Yamaori S, Maeda C, Yamamoto I, Watanabe Ok. Differential inhibition of human cytochrome P450 2A6 and 2B6 by main phytocannabinoids. Forensic Toxicol 2011;29:117-24.
Yamaori S, Okamoto Y, Yamamoto I, Watanabe Ok. Cannabidiol, a significant phytocannabinoid, as a potent atypical inhibitor for CYP2D6. Drug Metab Dispos 2011;39(11):2049-56. View summary.
Yeshurun M, Shpilberg O, Herscovici C, et al. Cannabidiol for the prevention of graft-versus-host-disease after allogeneic hematopoietic cell transplantation: outcomes of a section II research. Biol Blood Marrow Transplant. 2015 Oct;21(10):1770-5. View summary.
Yu JS, Premkumar A, Liu S, Sculco P. Charges of self-directed perioperative cannabidiol use in sufferers present process complete hip or knee arthroplasty. Ache Manag 2021;11(6):655-660. View summary.
Zuardi AW, Cosme RA, Graeff FG, Guimaraes FS. Results of ipsapirone and cannabidiol on human experimental nervousness. J Psychopharmacol 1993;7(1 Suppl):82-8. View summary.
Zuardi AW, Crippa JA, Hallak JE, et al. Cannabidiol for the therapy of psychosis in Parkinson’s illness. J Psychopharmacol 2009;23(8):979-83. View summary.
Zuardi AW, Crippa JA, Hallak JE, et al. Cannabidiol, a Hashish sativa constituent, as an antipsychotic drug. Braz J Med Biol Res 2006;39(4):421-9. View summary.
Zuardi AW, Rodriguez JA, Cunha JM. Results of cannabidiol in animal fashions predictive of antipsychotic exercise. Psychopharmacology (Berl) 1991;104(2):260-4. View summary.
Zuardi AW. Cannabidiol: from an inactive cannabinoid to a drug with broad spectrum of motion. Rev Bras Psiquiatr 2008;30(3):271-80. View summary.